CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
- Confirmatory Phase 3 Trial Designed to Support Commercialization of Multikine for Head and Neck Cancer Treatment
- Full enrollment expected by Q2 2026 with plans to seek early approval at that time based on early tumor responses—Potential to set a new standard of care
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) today announced it is in the final stages for the launch of its 212-patient Confirmatory Registration Study for Multikine* (Leukocyte Interleukin, Injection) in newly diagnosed locally advanced head and neck cancer patients. This final Registration Study is specifically designed to confirm the statistically significant efficacy and safety results from CEL-SCI’s previously completed randomized controlled Phase 3 trial.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250220081468/en/
Multikine is given via injection for 3 weeks after diagnosis and before surgery. The pre-surgical tumor responses shown in the chart demonstrate that patients whose tumors shrink in response to Multikine are more likely to have longer survival. (Graphic: Business Wire)
This new Registration Study targets the population of previously untreated resectable stage 3 and 4 head and neck cancer patients who had no lymph node involvement and low PD-L1 tumor expression. During the completed Phase 3 clinical trial, the 5-year survival rate of the target patient population increased to 73% when patients were treated with Multikine vs 45% for control patients who received only the standard of care treatments.
Key aspects of the new Confirmatory Registration Study are as follows:
- Enlisting clinical sites and investigators in numerous countries across 3 continents
- Full enrollment expected by Q2 2026 with plans to seek early approval at that time based on early tumor responses—Potential to set a new standard of care
- FDA concurred with the overall design of the Registration Study in meetings last year
- Final clinical protocol submitted to FDA in December 2024
- Multikine extended median overall survival by nearly 4 years in prior Phase 3 study
- A new model for healthcare—Immunotherapy given before surgery to boost the immune system and make the first cancer treatment more successful - may set the first new standard of care in more than half a century
“Now that the clinical protocol for our final marketing Registration Study has been submitted, we are proceeding to sign up investigators and open clinical sites. We are receiving a very positive response and high levels of interest from head and neck cancer physicians who see the abundance of data on Multikine and want to deliver this option to their patients,” stated CEL-SCI CEO Geert Kersten. “We believe that this small 212-patient trial will enroll relatively quickly precisely because Multikine has proven what it can do in terms of safety and efficacy in this specific target patient population which has not had a new option for treatment in decades.”
“We are very confident in this Registration Study’s chance of success since we already know that this type of patient showed an almost 4 year increase in median survival in our last study. The many studies we have done have helped us figure out who benefits from the drug and who does not. Early tumor responses measured after treatment with Multikine and prior to surgery have been shown to be correlated with 5-year overall survival outcomes. We plan to seek accelerated and/or conditional marketing approval based on this finding. Data regarding early tumor responses following Multikine treatment should become available shortly after the last patient has been treated, expected by the second quarter of 2026,” Kersten concluded.
CEL-SCI has been advised by a biostatistician with expertise in the design and analysis of oncology studies that this final Confirmatory Registration Study has an over 95% chance of success because it will include only the target population of patients who benefited most from Multikine in the prior Phase 3 study. These patients had much longer overall survival and had tumor responses including size reduction and total tumor elimination confirmed by pathology following three weeks of Multikine treatment. The favorable efficacy results in this target patient population exhibited a hazard ratio of 0.35 with an upper 95% confidence interval of 0.66, therefore CEL-SCI can expect (at 95%) to reach a favorable hazard ratio in the Confirmatory Registration Study.
There were no safety signals identified, Multikine administration did not interfere with disease directed treatment/therapy, and Multikine did not add to the treatment burden imparted by the standard of care.
Following the U.S. Food and Drug Administration’s (FDA) go-ahead to conduct the Registration Study, CEL-SCI finalized the clinical protocol based on constructive comments from FDA reviewers and senior staff. The final clinical protocol was submitted to the FDA in December 2024. The study is titled:
“A Phase III, Open Label, Randomized, Controlled, Multi-Center Study of the Effects of Neoadjuvant Leukocyte Interleukin, Injection (LI) Plus Standard of Care Versus Standard of Care Only in Treatment Naïve Adults With Resectable Locally Advanced Primary Squamous Cell Carcinoma of the Head and Neck (Oral Cavity) Who Present With No Nodal Involvement and Low Tumor Programmed Death Ligand 1 Expression (Defined as Tumor Proportion Score
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.